Study Randomization and Treatment Regimens
Eligible participants were randomized in a 1:1:1 ratio with a simple randomization method using an interactive web response system to the 3 intervention groups. Participants received either oral rivaroxaban 2.5 mg, rivaroxaban 5 mg, or subcutaneous enoxaparin (1 mg/kg) twice daily until discharge or 12 hours before revascularization therapy for up to 8 days. All participants received DAPT (100 mg aspirin and 75 mg clopidogrel once daily), and DAPT was continued when indicated after discharge. The protocol of periprocedural antithrombotic management is summarized in eAppendix 2 in 